A day-by-day investigation of changes in criminal convictions before and after entering and leaving opioid maintenance treatment: a national cohort study by unknown
Bukten et al. BMC Psychiatry 2013, 13:262
http://www.biomedcentral.com/1471-244X/13/262RESEARCH ARTICLE Open AccessA day-by-day investigation of changes in criminal
convictions before and after entering and
leaving opioid maintenance treatment: a national
cohort study
Anne Bukten1*, Jo Røislien1,2, Svetlana Skurtveit1,3, Helge Waal1, Michael Gossop1,4 and Thomas Clausen1Abstract
Background: Opioid maintenance treatment (OMT) is associated with reduced crime among heroin users, but little
is known about how crime changes during different phases of treatment. The aim of this study was to investigate
changes in criminal convictions on a day-to-day basis before and after entry or discharge from OMT.
Methods: National cohort study of all patients (n = 3221) in OMT in Norway 1997-2003. Patients were followed over
a 9-year period, before, during, and after treatment. Criminal convictions were studied on a day-to-day basis in
relation to treatment status. A time-continuous estimate of the probability of convictions within the population for
all days during observation was calculated.
Results: Changes in convictions were evident before changes of treatment status. During the 3 years prior to OMT,
the convictions rate was approximately 0.4% per day. Prior to OMT, convictions decreased to about 0.2% per day
on the day of treatment initiation. During the weeks before dropping out of treatment, convictions increased.
The patterns during periods of transition were the same across gender, age and pre-treatment conviction-levels.
Conclusions: Changes in convictions often occurred prior to changes in treatment status. Reductions in criminal
convictions were found in the period before entry (or re-entry) to OMT, and increases in criminal activity were
found in the months prior to treatment interruption.Background
In treating heroin-dependent persons, opioid maintenance
treatment (OMT) combined with psychosocial support
has been found to be effective [1,2], and has been linked
to improvements in a number of outcomes, including her-
oin use [3,4], mortality [5-8] and criminal activity [9-15].
OMT is often considered a long-term treatment. However,
attrition and relapses are major challenges in OMT; treat-
ment compliance is often poor and dropout from treat-
ment is common [16,17]. Patients who cycle in and out of
treatment typically show less improvement during treat-
ment [9,18] and relapse to more drug use and criminal ac-
tivity when out of treatment [4,9,19]. For patients with* Correspondence: anne.bukten@medisin.uio.no
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reproduction in any medium, provided the orseveral treatment episodes, the high-risk periods outside
of treatment are of special concern.
Studies examining the effects of OMT on criminal ac-
tivity have typically compared levels of criminal involve-
ment which have been aggregated for specific blocks of
time, e.g., the period before treatment, during treatment
and after treatment [9,20], and the mean total amount of
criminal involvement in one period is compared with
that in another period. However, categorizing the time
axis into blocks of time effectively removes an important
variable describing outcomes in the dynamic process of
treatment, namely the continuity of change over time.
Hence, comparing total amounts of crime aggregated for
time periods does not optimally describe the time-varying
and continuous probability of criminal activity within the
different phases inside and outside of treatment. Because
drug users move through different stages of both addic-
tion and treatment, a more sensitive longitudinal approachLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Bukten et al. BMC Psychiatry 2013, 13:262 Page 2 of 7
http://www.biomedcentral.com/1471-244X/13/262may be required to identify and understand key factors in-
fluencing drug use and treatment over time [20,21].
Although a more time-continuous approach has been
used for investigating high-risk periods of mortality as-
sociated with the changes in treatment status, such stud-
ies have typically considered the weeks immediately after
treatment induction and cessation, and compared these
short-time risk intervals with the average risk over lon-
ger time periods [6,21]. In contrast, our study compares
the criminal activity during all days before, during and
after treatment as a time-continuous variable.
The present study investigates criminal convictions on
a day-to-day basis and over prolonged periods of time
for all days before, during and after treatment. The main
purpose of the study was to investigate on a day-by-day
basis the criminal convictions in a national Norwegian co-
hort of patients in opioid maintenance treatment. More
specifically, the study investigates changes in criminal con-
victions during the time periods before and after entering,
re-entering, and leaving treatment.
Methods
Nationwide registers on all patients (n = 3221) who en-
tered OMT in Norway were cross linked with official data
from the Norwegian crime statistics (Statistics Norway)
using the unique 11-digit identification number, assigned
by the Norwegian state for all citizens. The Norwegian
crime statistics comprised detailed information of all cases
registered by the police, including the date of the criminal
incident and offence details. The OMT patient records in-
cluded information on age and gender, and the exact date
of treatment entries, re-entries, and discharges.
Study setting
In Norway, OMT is only available through a single pub-
licly funded programme that is provided in all treatment
centres and which has a monopoly in respect to OMT ad-
missions [22]. The programme has been available on a na-
tional level since 1998, and is integrated into the general
health and social service systems [23]. In the study period,
patients applied to OMT on a standardized form via their
social service centre, and applications were registered in
the regional OMT centre [22]. The Norwegian model can
be characterized as rehabilitation oriented [22], consisting
of both non-medical interventions targeted at housing and
psychosocial aspects as well as the maintenance medica-
tion. The general practitioner (GP) plays an important and
integrated role in the Norwegian OMT system. In 2010,
68% of patients were prescribed OMT medications by
their GP although all treatment initiations were conducted
at the regional OMT centres [24]. At the time of our ob-
servation period, the OMT programme could be consid-
ered as relatively high threshold and restrictive: the criteria
for admission specified that patients should be 25 years ofage, dependent on heroin for several years, and to have ex-
perienced prior abstinence-oriented treatment, though in-
terpretation of these criteria was not rigid [22].
Termination of treatment could be either voluntary or
involuntary. The absolute criteria for involuntary termi-
nations were violence and threats, but treatment could
also be terminated in cases of continued substance abuse,
lack of treatment cooperation and lack of rehabilitation effi-
cacy [25]. Very few discharges were made on the basis of
the absolute criteria. A few patients decided to leave treat-
ment voluntarily because they considered treatment a suc-
cess and wanted to become drug-free, while most patients
simply dropped out of treatment by discontinuing their at-
tendance of the programme. Dropout for reasons related to
convictions, for example incarceration, are considered to be
unlikely. According to the national guidelines at the time of
observation, patients in OMT could receive OMT-drugs in
prison, during periods on remand or short sentences. Fol-
lowing potential treatment termination, the only possibility
to obtain access to OMT was to apply for readmission [22].
Participants
All patients (n = 3221) in Norway who started OMT from
September 15th 1997 until December 31st 2003 were in-
cluded. The study period consisted of varying observation
periods for each individual; from admission to OMT until
the last day of observation (December 31st), creating a dy-
namic cohort. The pre-treatment period was defined as
the three years prior to each individual’s treatment start.
Some patients (n = 135) died between treatment start
and the last day of observation, and their observation time
was censored at the date of death. “Treatment start” is the
date first receiving maintenance medication with either
methadone or buprenorphine.
The Norwegian crime statistics provided data on date of
the criminal event, penal code and four prosecuting deci-
sions: formal charge leading to conviction, formal charge
leading to acquittal, fines, and other. All convictions are
decisions finding a person guilty of a crime in the court of
law. In our study, only formal charges leading to convic-
tions were included in the analysis. A description of types
of convictions that the cohort accounted for can be found
in previous publications [14,20,26].
A person may have had several convictions during a
single day, e.g. being convicted for both stealing a car
and for driving under the influence. In our study, the
unit of observation was a ‘crime-day’, defined as a day an
individual had one or more criminal offences leading to
convictions. The crime-day represents the day that the
crime was committed.
Patient subgroups
In addition to an overall estimate of criminal convictions
in the cohort, data were stratified according to gender,
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were categorized into three groups according to age at
treatment start; below 30 (n = 450), 30-40 (n = 1797),
and above 40 years (n = 974). Patients were similarly di-
vided into three groups according to levels of convictions
during the 3 years prior to treatment start; patients with
no convictions (n = 1375), 1-27 convictions (n = 1659),
and more than 27 convictions (n = 187), comprising the
90-percentile of patients having the most criminal convic-
tions during the pre-treatment period. These categories
were labelled the “no conviction group”, “medium convic-
tion group” and “high conviction group”, respectively.
All patients were included when estimating the prob-
ability of criminal convictions at the time of entry to the
first treatment episode. When calculating rates of criminal
convictions during the period of treatment drop-out, all pa-
tients who dropped out of treatment at least once (n =
1175) were included in the analysis. All patients having sev-
eral individual treatment episodes (n = 515) were included
when calculating rates of criminal convictions during the
period prior to treatment re-entry.
Ethics
The study was approved by the Regional Committees for
Medical and Health Research Ethics, The Norwegian Social
Science Data Services (NSD), the Norwegian Directorate
of Health and the Police Directorate. Files were merged
and made anonymous by Statistics Norway.
Statistical analysis
Data are presented as mean (SD) or n (%). Continuous
variables were compared using t-tests and discrete vari-
ables using chi-square tests. The number of crime-days at
a specific given time, measured relative to entering, re-
entering or leaving treatment, divided by the number of
patients observed at that time, is an estimate of the prob-
ability of a criminal activity at that time [27]. Calculating
this probability for all times, i.e. all days when patients
were observed, provides a time continuous estimate of the
probability of criminal in the cohort on each day. Two es-
sential times; “date of treatment entry (or re-entry)” and
“date of treatment termination” were used as reference
dates for which the day-by day probability of criminal con-
victions was calculated both before and after. In order to
reduce the effect of natural day-to-day variation, the esti-
mate was smoothed using a Gaussian Kernel [28]. A time
continuous 95% confidence interval (CI) was calculated
using bootstrapping [29], a general statistical re-sampling
methodology. Statistical analyses were performed in R ver-
sion 2.12 and Stata version 11.
Results
The patients in the cohort had a mean age of 37 years at
treatment entry and the majority (67.6%) were men (seeTable 1). Women were significantly younger than men
(35.5 vs. 37.7 years) at entry to OMT, and spent slightly
longer time in treatment than men. No differences were
found between men and women in likelihood of drop-
ping out of treatment or in having several treatment
episodes.
Prior to first treatment entry, the rate of criminal convic-
tions was generally high, with a daily rate of criminality
within the cohort of approximately 0.4% per day (Figure 1a).
However, about three months prior to treatment initiation,
the rate of criminal convictions gradually fell to a lower
level, at about 0.2% per day at the day of treatment initi-
ation. This lower level was maintained throughout most of
the treatment period (Figure 1a).
During the two months prior to treatment termination
the rate of convictions again gradually rose, reaching a
higher level around the day of treatment dropout. This
increased level prior to treatment dropout is somewhat
higher than the pre-treatment level but with wide confi-
dence intervals due to fewer observations with 35% (n =
1175) of patients dropping out at least once (Figure 1b).
For those drug users who re-entered treatment, this
higher crime level after leaving treatment was continued
until approximately three months before re-entering treat-
ment, when it again fell to a lower level of about 0.2%
(Figure 1c). Compared to the period prior to the first epi-
sode of treatment, the rate of criminal convictions was
higher during the period before re-entering OMT.
There was a slight gender difference with a signifi-
cantly higher level of criminal activity among men as
compared to women. Consequently the differences be-
tween in-treatment and out of treatment periods were
less marked among women. When data were stratified
by age groups, the middle age-group (30-40 years) had a
rate of convictions similar to the mean of the total co-
hort. In comparison, patients under 30 had a slightly
higher level, and those over 40 had a slightly lower level.
When data were stratified by pre-treatment levels of crim-
inal convictions, the high conviction group had a substan-
tially elevated risk of criminal convictions compared to
patients with no or medium criminal convictions during
the entire period of observation. The medium conviction
group had a time continuous pattern similar to that of the
overall mean, but with somewhat less crime out of treat-
ment, i.e. a less obvious difference between in and out of
treatment. Similar time-related patterns of convictions were
found for all age subgroups.
Discussion
The main finding in this study was that although convic-
tion rates were broadly related to treatment status (in
and out of treatment), changes in criminal behaviour
tended to occur gradually and did not coincide in any
precise way with entry to treatment or leaving treatment.
Table 1 Demographics for OMT patients in Norway (1997-2003) (n = 3221)
Characteristics of patients and treatment episodes All patients Male Female P-valuea
Patients (n, %) 3221 (100) 2176 (67.6) 1045 (32.4)
Age at treatment start (mean, SD) 37.0 (6.7) 37.7 (6.6) 35.5 (6.6) < 0.001
Age groups (n, %)
< 30 450 (14.0) 254 (11.7) 196 (18.8) < 0.001
30-40 1797 (55.8) 1185 (54.5) 612 (58.6) < 0.001
> 40 974 (30.2) 737 (33.9) 237 (22.7) < 0.001
Continuous treatment (n, %) 2046 (63.5) 1391 (63.9) 655 (62.7) 0.492
Dropout (n, %) 1175 (36.5) 785 (36.1) 390 (37.3) 0.492
1 treatment episode 660 (20.5) 440 (20.2) 220 (21.1) 0.584
2 treatment episodes 434 (13.5) 294 (13.5) 140 (13.4) 0.929
3+ treatment episodes 81 (2.5) 51 (2.3) 30 (2.3) 0.371
Months in waiting-list, (median, SD) 5.30 (11.78) 5.49 (11.84) 4.90 (11.65) 0.099
Years in treatment, continuous (median, SD) 1.97 (1.52) 1.94 (1.52) 2.05 (1.55) 0.059
Years in treatment, drop out (median, SD) 1.26 (1.28) 1.22 (1.21) 1.36 (1.39) < 0.05
Months between treatment (median, range)b 2.7 (0-51.9) 3.2 (0-51.9) 2.4 (0-50) 0.187
Months after treatment (median, range)c 13.1 (0-58.9) 13.1 (0.2-58.9) 13.2 (0-50.5) 0.791
aP-value for gender difference. bBetween treatment period: sum of months between treatment episodes. cThe post-treatment period: sum of months after
ending treatment.
Bukten et al. BMC Psychiatry 2013, 13:262 Page 4 of 7
http://www.biomedcentral.com/1471-244X/13/262Changes in criminal convictions were already evident be-
fore changes of treatment status. Reductions in criminal
convictions were found in the period before entry (or re-
entry) to OMT, and increases in criminal activity were
found in the months prior to treatment interruption. As
in other studies [9,13], the rates of criminal convictions
continued to be relatively low when patients were in treat-
ment, whereas outside of treatment the rates of criminal
convictions continued to be relatively high. Although dif-












































Figure 1 Day-to-day rates of criminal convictions. Day-to-day rates of c
first time, (b) leaving OMT and (c) re-entering OMT. a: X-axis; days before a
of criminal convictions. b: X-axis; days before and days after treatment drop
c: X-axis; days before and days after treatment re-entry (n=515). Y-axis; thebefore and after treatment entry for patients differing in
age, gender and pre-treatment convictions, the same over-
all pattern of change was evident for all sub-groups.
Criminal convictions may be considered as a proxy on
other types of problem behaviour, such as intensive sub-
stance abuse [30,31] and previous studies have reported
that sizable numbers of treatment seeking people began
making changes in substance use prior to treatment
entry [32,33]. In a study investigating pre-treatment ab-
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prior to entering treatment [32]. Several factors may have
contributed to the observed changes that occurred in
criminal convictions prior to OMT. Individual factors such
as problem recognition, awareness of need for change,
willingness to receive treatment and commitment to par-
ticipate in treatment may also have acted as factors affect-
ing treatment engagement and reduction or cessation of
drug use [34,35]. By actively applying for treatment, a
process of change may have been initiated and supported,
which may have led to less drug use and consequently less
criminal convictions. Also, the changes may have been in-
directly related to treatment: the reduction that was found
in levels of criminal convictions in the months before ini-
tiation to treatment, corresponds approximately to the
waiting list period, i.e. the period between application and
treatment start. During the process of applying for OMT,
patients may have established contact with the health and
social services, and, for example, set up for long-term liv-
ing arrangements [22]. More stable living and social condi-
tions may have contributed to the reduction in criminal
convictions prior to treatment initiation.
OMT is offered as a long-term or lifelong treatment. In
practice, however, interruptions of treatment are common
[16,36], and premature dropout is a usual problem facing
patients, practitioners, and clinical researchers [17]. In our
study, more than 35% of patients dropped out of treatment
during the observation period, and some had multiple
treatment episodes with entering and discontinuation of
treatment. During the months prior to discontinuing treat-
ment, the risk of criminal convictions gradually increased,
and reached a higher level outside of treatment. The first
few weeks after treatment cessations have been described
as a critical period [37] both in terms of relapse to drug
use and risk of overdose mortality [37-39]. The findings
from the present study showed that the period of in-
creased risk can be seen to precede the discontinuation of
treatment. The elevated risk of convictions prior to treat-
ment termination may be an indication of more chaotic
personal circumstances at this time, resulting in increased
drug use and as a consequence increased criminal activity.
Drug users may experience a number of incomplete or
discontinued treatment attempts before being retained
in long term maintenance treatment. Patients who have
multiple episodes of maintenance treatment have been
found to stay in treatment for progressively longer periods
in later episodes [40], and readmission to more than one
treatment episode may be protective of overdose mortality
[39]. In the present study, patients with several treatment
episodes showed significant reductions in criminal convic-
tions prior to re-entering treatment as when entering
treatment for the first time. This suggests that services
should be prepared to readmit patients with previous in-
complete or failed treatment attempts. Treatment policiesthat seek to restrict readmission to maintenance treatment
may be counterproductive. Equally, clinical staff should be
alert to the fact that there may be increased levels of crim-
inal convictions before leaving treatment with attendant
risks of increased drug use, morbidity, and drug related
mortality in the period prior to treatment drop out.
The finding that changes in criminal convictions often
occurred prior to changes in treatment status suggests
that the factors associated with criminal activity may be,
at least in part, independent of the treatment effects,
and that such factors are located outside of the immedi-
ate context of treatment. This is consistent with other
studies that have found reductions or cessation of sub-
stance use prior to treatment entry [32,33], and with
studies that have shown the powerful effects that psy-
chosocial factors can have upon relapse to illicit drug
use during treatment [41].
Limitations
Certain limitations of this study should be taken into ac-
count. Our study did not include data on self-reported
criminal activity. Official crime records are known to
underestimate the actual frequency of criminal activity,
and crime statistics are considered a crude measure of
heroin users’ involvement in crime. However, since this
study investigates changes in criminal convictions during
different phases of treatment, the patterns of criminal
convictions are more important than the actual preva-
lence of criminal activity. Interpretation of our findings
also needs to take account of potential confounding fac-
tors. Our study did not include data on whether patients
spent time in prison, hospital or other institutions, or
were in some other contact with other treatment services
during periods of observation. Also, information was not
available on whether patients ended treatment for non-
compliance with programme requirements, or were vol-
untarily discharged. Important strengths of our study were
having a complete national cohort of OMT patients, with
no loss of patients during follow-up, and having a long ob-
servation period of nine years. Complete lists of patients
allowed us to investigate the time periods when patients
were outside of treatment. The criminal records have a
further advantage in that they do not have gaps in the re-
cording of criminal events throughout the lengthy study
period. As all criminal offences were recorded for the spe-
cific date of the criminal offence, it was possible to calcu-
late rates of criminal convictions on a day-to-day basis
throughout the total observation period.
Despite the study limitations our results add to the un-
derstanding of the changes in behaviour that may occur
among drug users seeking and receiving opioid mainten-
ance treatment. The changes in problem behaviours that
occur after entry to opioid maintenance treatment have
been extensively studied. The changes that occur prior
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ment) have received relatively little research attention.
The finding that changes in criminal convictions often
occurred prior to changes in treatment status suggests
that the factors associated with criminal activity may be
independent of the treatment effects, and that such factors
are located outside of the immediate context of treatment.
This is consistent with other studies that have found re-
ductions or cessation of substance use prior to treatment
entry [32,33], and with studies that have shown the power-
ful effects that psychosocial factors can have upon relapse
to illicit drug use during treatment [41].
Conclusions
The results of the present study suggest that an important
purpose of treatment may be to consolidate rather than to
initiate behaviour change. The treatment of drug addiction
is always a collaborative enterprise and drug problems
cannot be treated without the co-operation and commit-
ment of the patient [42]. More generally, the results sup-
port the utility of a broader temporal perspective upon the
process of behaviour change that is not associated exclu-
sively with the effects of the treatment intervention.
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